✨ Medicines Act Notices
23 MARCH
NEW ZEALAND GAZETTE
793
Medicines Act 1981
Corrigendum
Consent to the Distribution of Changed Medicines
In the notice published in the New Zealand Gazette, 4 August 1994, No. 77, page 2477, notice No. 5767, for the strength “0.21%” in the thirty-second line, replace the strength “0.12%”. This in respect of potassium chloride for the product Sensitive Eyes Saline K*.
Dated this 20th day of March 1995.
TONY JOHNS, Acting Director-General of Health, pursuant to the delegation given by the Minister of Health on the 25th day of June 1993.
go1976
Consent to the Distribution of New Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines set out in the Schedule hereto:
Schedule
| Name and Strength | Form | Name and Address of Manufacturer | Proprietary Name (if any) |
|---|---|---|---|
| Molgramostim 50 mcg (0.555 x 10^6 IRU), 150 mcg (1.67 x 10^6 IRU), 300 mcg (3.33 x 10^6 IRU), 400 mcg (4.44 x 10^6 IRU), 700 mcg (7.77 x 10^6 IRU) | Powder for injection (with diluent) | Schering-Plough (Brinn) Chemical Co., Innishannon, County Cork, Ireland | Leucomax |
| Calcium carbonate 500 mg, simeticone 20 mg | Tablet | Sterling Winthrop Pty Limited, Ermington, New South Wales, Australia | Andrews |
| Ipratropium bromide monohydrate 21 mcg (equivalent to 20 mcg ipratropium bromide), salbutamol sulphate 120 mcg (equivalent to 100 mcg salbutamol base) per actuation in 5 ml and 10 ml | Oral metered dose spray | Boehringer Ingelheim France SARL, Reims, France | Combivent Metered Dose Inhaler |
| Benzydamine hydrochloride 0.15% w/v, chlorhexidine gluconate 0.12% w/v | Topical solution | 3M Pharmaceuticals Australia Pty Limited, Thornleigh, New South Wales, Australia | Difflam-C Solution |
| Benzydamine hydrochloride 0.15% w/v, chlorhexidine gluconate 0.12% w/v | Topical solution | 3M Pharmaceuticals Australia Pty Limited, Thornleigh, New South Wales, Australia | Difflam Dental Solution |
| 21 formulations of an aqueous solution comprising various combinations of the following: potassium chloride 0 to 7 g/L, sodium chloride 171.9 to 284.0 g/L, calcium chloride (dihydrate) 0 to 10.3 g/L, magnesium chloride (hexahydrate) 0 to 4.8 g/L, acetic acid 5.4 to 11.2 g/L | Dialysis solutions | Ajax Chemicals, Smithfield, New South Wales, Australia | Concentrated Bicarbonate Haemodialysis Solution (component A) |
| 24 formulations of an aqueous solution comprising various combinations of the following: acetic acid 73.6 to 90.4 g/L, sodium hydroxide 50.2 to 61.7 g/L, potassium chloride 0 to 10.4 g/L, sodium chloride 192.3 to 214.8 g/L, calcium chloride (dihydrate) 6.7 to 9.8 g/L, magnesium chloride (hexahydrate) 0 to 5.3 g/L, dextrose 0 to 96.3 g/L | Dialysis solutions | Ajax Chemicals, Smithfield, New South Wales, Australia | Concentrated Acetate Haemodialysis Solution |
Dated this 20th day of March 1995.
TONY JOHNS, Acting Director-General of Health, pursuant to the delegation given by the Minister of Health on the 25th day of June 1993.
go1977
Next Page →
PDF embedding disabled (Crown copyright)
View this page online at:
VUW Te Waharoa —
NZ Gazette 1995, No 26
NZLII —
NZ Gazette 1995, No 26
✨ LLM interpretation of page content
🏥 Corrigendum to Consent for Distribution of Changed Medicines
🏥 Health & Social Welfare20 March 1995
Medicines Act, Corrigendum, Potassium chloride, Sensitive Eyes Saline K
- TONY JOHNS, Acting Director-General of Health
🏥 Consent to the Distribution of New Medicines
🏥 Health & Social Welfare20 March 1995
Medicines Act, New medicines, Molgramostim, Calcium carbonate, Ipratropium bromide, Benzydamine hydrochloride, Dialysis solutions
- TONY JOHNS, Acting Director-General of Health